OncoC4 Reports First Patient Dosing of ONC-392 + Keytruda (pembrolizumab) in P-II Study (PRESERVE-004) for Platinum-Resistant Ovarian Cancer
Shots:
- The first patient has been dosed in the P-II study (PRESERVE-004) evaluating ONC-392 (3/6mg/kg) + Keytruda (200mg) in patients with PROC for ~24mos. at the prespecified interval of q3w. The study is sponsored by OncoC4 in collaboration with Merck & GOG Foundation Inc.
- The study was based on the promising prior clinical trial results of the monotherapeutic activity of ONC-392. The 1EP of the study is the efficacy measured by ORR per RECIST1.1, and the safety measured by TRAEs and immune-related AEs
- ONC-392 is the first known acid pH-sensitive anti-CTLA-4 mAb & is currently being evaluated in late-stage clinical development. The therapy has received FTD from the US FDA as a monotx. for immunotherapy-resistant NSCLC
Ref: Globe Newswire | Image: Novavax
Related News:- ImmunoGen’s Elahere Receive the US FDA’s Approval for the Treatment of Platinum-Resistant Ovarian Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
